JP2021042151A - Agent for inhibiting sebum production or accumulation, agent for preventing or improving dyskeratosis, and agent for preventing or improving acne - Google Patents
Agent for inhibiting sebum production or accumulation, agent for preventing or improving dyskeratosis, and agent for preventing or improving acne Download PDFInfo
- Publication number
- JP2021042151A JP2021042151A JP2019164297A JP2019164297A JP2021042151A JP 2021042151 A JP2021042151 A JP 2021042151A JP 2019164297 A JP2019164297 A JP 2019164297A JP 2019164297 A JP2019164297 A JP 2019164297A JP 2021042151 A JP2021042151 A JP 2021042151A
- Authority
- JP
- Japan
- Prior art keywords
- agent
- acne
- preventing
- accumulation
- improving
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000002374 sebum Anatomy 0.000 title claims abstract description 54
- 208000002874 Acne Vulgaris Diseases 0.000 title claims abstract description 46
- 206010000496 acne Diseases 0.000 title claims abstract description 46
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 44
- 238000009825 accumulation Methods 0.000 title claims abstract description 41
- 230000002401 inhibitory effect Effects 0.000 title abstract description 7
- 230000003780 keratinization Effects 0.000 claims description 33
- 230000005856 abnormality Effects 0.000 claims description 29
- 230000003449 preventive effect Effects 0.000 claims description 18
- 239000003795 chemical substances by application Substances 0.000 description 53
- 230000002265 prevention Effects 0.000 description 42
- 230000006872 improvement Effects 0.000 description 22
- 239000000203 mixture Substances 0.000 description 17
- 239000003112 inhibitor Substances 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- 230000000694 effects Effects 0.000 description 14
- 239000006228 supernatant Substances 0.000 description 11
- 239000003826 tablet Substances 0.000 description 11
- 239000011148 porous material Substances 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
- 102000011782 Keratins Human genes 0.000 description 9
- 108010076876 Keratins Proteins 0.000 description 9
- 235000013305 food Nutrition 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 8
- 210000003491 skin Anatomy 0.000 description 8
- 239000008187 granular material Substances 0.000 description 7
- 230000028327 secretion Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 6
- 238000004806 packaging method and process Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000003925 fat Substances 0.000 description 5
- 235000013402 health food Nutrition 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 241000186427 Cutibacterium acnes Species 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 4
- 239000007910 chewable tablet Substances 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 229930002330 retinoic acid Natural products 0.000 description 4
- -1 sucrose fatty acid ester Chemical class 0.000 description 4
- 241000699800 Cricetinae Species 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000010426 asphalt Substances 0.000 description 3
- 229910002091 carbon monoxide Inorganic materials 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 210000001732 sebaceous gland Anatomy 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- PUKLDDOGISCFCP-JSQCKWNTSA-N 21-Deoxycortisone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2=O PUKLDDOGISCFCP-JSQCKWNTSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- FCYKAQOGGFGCMD-UHFFFAOYSA-N Fulvic acid Natural products O1C2=CC(O)=C(O)C(C(O)=O)=C2C(=O)C2=C1CC(C)(O)OC2 FCYKAQOGGFGCMD-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 239000002509 fulvic acid Substances 0.000 description 2
- 229940095100 fulvic acid Drugs 0.000 description 2
- 210000003780 hair follicle Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 229940055019 propionibacterium acne Drugs 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 235000019871 vegetable fat Nutrition 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 1
- QJZYHAIUNVAGQP-UHFFFAOYSA-N 3-nitrobicyclo[2.2.1]hept-5-ene-2,3-dicarboxylic acid Chemical compound C1C2C=CC1C(C(=O)O)C2(C(O)=O)[N+]([O-])=O QJZYHAIUNVAGQP-UHFFFAOYSA-N 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- IBFXLTFIVWRUQC-OVGYCKTGSA-N 9b,10b-epoxyroridin d Chemical compound C([C@@]12[C@]3(C)[C@H]4C[C@H]1OC1C5OC5(C)CCC13COC(=O)C1O[C@@]1(C)CCOC(\C=C\C=C/C(=O)O4)C(O)C)O2 IBFXLTFIVWRUQC-OVGYCKTGSA-N 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QQXDYWHKPKEBJU-UHFFFAOYSA-N CCCCCCCCCCCCCCCCCC[Na] Chemical compound CCCCCCCCCCCCCCCCCC[Na] QQXDYWHKPKEBJU-UHFFFAOYSA-N 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical compound [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940108925 copper gluconate Drugs 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000004387 flavanoid group Chemical group 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 238000005243 fluidization Methods 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Substances O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 229940025878 hesperidin Drugs 0.000 description 1
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 1
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 1
- 239000004021 humic acid Substances 0.000 description 1
- 239000003864 humus Substances 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229940088417 precipitated calcium carbonate Drugs 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011670 zinc gluconate Substances 0.000 description 1
- 229960000306 zinc gluconate Drugs 0.000 description 1
- 235000011478 zinc gluconate Nutrition 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
本発明は、皮脂の産生又は蓄積を抑制する組成物に関する。 The present invention relates to a composition that suppresses the production or accumulation of sebum.
近年、健康志向や安全志向の高まりを背景に、食品分野や化粧品分野においては、天然素材を用いたものが好まれ、このような天然素材がもつ有用な機能をより活用することが望まれている。 In recent years, against the background of increasing health consciousness and safety consciousness, those using natural materials are preferred in the food field and cosmetics field, and it is desired to further utilize the useful functions of such natural materials. There is.
一方、ニキビは皮膚の病気であり、過剰な皮脂の分泌や、菌の繁殖が原因となる。このようなニキビを予防改善する食品組成物として、グルコン酸銅とグルコン酸亜鉛とを含有する食品組成物が提案されている（特許文献１参照）。 Acne, on the other hand, is a skin disease that is caused by excessive sebum secretion and bacterial growth. As a food composition for preventing and improving such acne, a food composition containing copper gluconate and zinc gluconate has been proposed (see Patent Document 1).
本発明の課題は、皮脂の産生又は蓄積を抑制することができる皮脂の産生又は蓄積抑制剤、角化異常の予防又は改善剤、ニキビの予防又は改善剤を提供することにある。 An object of the present invention is to provide an agent for suppressing the production or accumulation of sebum, an agent for preventing or improving keratinization abnormality, and an agent for preventing or improving acne, which can suppress the production or accumulation of sebum.
本発明者らは、各種天然素材の機能を探求する中で、シラジットが、皮脂の産生又は蓄積を抑制する効果を有し、角化異常の予防又は改善やニキビの予防又は改善に有効であることを見出し、本発明を完成するに至った。 While exploring the functions of various natural materials, the present inventors have the effect of suppressing the production or accumulation of sebum, and are effective in preventing or improving keratinization abnormalities and preventing or improving acne. This has led to the completion of the present invention.
すなわち、本発明は、以下のとおりのものである。
［１］シラジットを含有することを特徴とする皮脂の産生又は蓄積抑制。
［２］シラジットを含有することを特徴とする角化異常の予防又は改善剤。
［３］シラジットを含有することを特徴とするニキビの予防又は改善剤。
［４］経口用であることを特徴とする［１］記載の皮脂の産生又は蓄積抑制。
［５］経口用であることを特徴とする［２］記載の角化異常の予防又は改善剤。
［６］経口用であることを特徴とする［３］記載のニキビの予防又は改善剤。
That is, the present invention is as follows.
[1] Suppression of sebum production or accumulation, which is characterized by containing shilajit.
[2] A preventive or ameliorating agent for keratinization abnormality, which is characterized by containing shilajit.
[3] An acne preventive or ameliorating agent containing shilajit.
[4] Suppression of sebum production or accumulation according to [1], which is for oral use.
[5] The agent for preventing or ameliorating keratinization abnormality according to [2], which is for oral use.
[6] The acne preventive or ameliorating agent according to [3], which is for oral use.
本発明の皮脂の産生又は蓄積抑制剤、角化異常の予防又は改善剤、ニキビの予防又は改善剤は、皮脂の産生又は蓄積を有効に抑制することができる。 The sebum production or accumulation inhibitor, the keratinization abnormality prevention or ameliorating agent, and the acne prevention or ameliorating agent of the present invention can effectively suppress the production or accumulation of sebum.
本発明の皮脂の産生又は蓄積抑制剤、角化異常の予防又は改善剤、ニキビの予防又は改善剤は、シラジットを含有することを特徴とする。 The sebum production or accumulation inhibitor, the keratinization abnormality prevention or ameliorating agent, and the acne prevention or ameliorating agent of the present invention are characterized by containing shilajit.
本発明の皮脂の産生又は蓄積抑制剤は、皮脂の産生又は蓄積を有効に抑制することができる。したがって、角化異常の予防又は改善やニキビの予防又は改善に有効である。その他、肌のべたつきやテカリの予防又は改善（肌のべたつき予防又は改善剤、肌のテカリ予防又は改善剤）、角栓の予防又は改善（角栓の予防又は改善剤）、毛嚢漏斗部（毛穴）の閉塞予防又は改善（毛嚢漏斗部（毛穴）の閉塞予防又は改善剤）、アクネ菌（Propionibacterium acnes）の増殖予防又は改善（アクネ菌（Propionibacterium acnes）の増殖予防又は改善剤）、毛包内炎症の予防又は改善（毛包内炎症の予防又は改善剤）等にも有効である。 The sebum production or accumulation inhibitor of the present invention can effectively suppress the production or accumulation of sebum. Therefore, it is effective in preventing or ameliorating abnormal keratinization and preventing or ameliorating acne. In addition, prevention or improvement of skin stickiness and shine (skin stickiness prevention or improvement agent, skin shine prevention or improvement agent), prevention or improvement of keratin plug (prevention or improvement agent of keratin plug), hair follicle funnel (prevention or improvement agent of keratin plug) Prevention or improvement of obstruction of pores) (prevention or improvement agent of obstruction of hair follicle infundibulum (pores)), prevention or improvement of growth of P. acnes (Propionibacterium acnes), prevention or improvement of growth of P. acnes (Propionibacterium acnes), hair It is also effective in preventing or ameliorating intrafollicle inflammation (preventing or ameliorating agent for intrafollicle inflammation).
また、本発明の角化異常の予防又は改善剤は、皮脂の産生又は蓄積を有効に抑制することができ、毛穴の角化異常（毛穴の角層の硬質化、毛穴の出口の閉塞又は狭窄）の予防又は改善に有効である。 In addition, the preventive or ameliorating agent for abnormal keratinization of the present invention can effectively suppress the production or accumulation of sebum, and abnormal keratinization of pores (hardening of the stratum corneum of pores, obstruction or narrowing of the exit of pores). ) Is effective for prevention or improvement.
また、本発明のニキビの予防又は改善剤は、皮脂の産生又は蓄積を有効に抑制することができ、ニキビの予防又は改善に有効である。 In addition, the acne preventive or ameliorating agent of the present invention can effectively suppress the production or accumulation of sebum and is effective in the prevention or amelioration of acne.
［シラジット］
本発明の皮脂の産生又は蓄積抑制剤等に用いられるシラジットは、一般名をミネラルピッチといい、学名は、Asphaltum、Asphaltum puniabiunum又はAsphaltum Punjabinumである。このシラジットは、ヒマラヤ山脈の高度１０００〜５０００ｍの高地で採取される天然の腐植土と植物性有機物の混合物であり、その成分として、フルボ酸、フミン質などの貴重な４０超のミネラルを含む。本発明に用いるシラジットは、好ましくはフルボ酸を５質量％以上含み、より好ましくは１０質量％以上含み、特に好ましくは２０質量％以上含む。本発明においては、市販品を用いることができる。形状としては、特に制限されるものではないが、粉末状が好ましい。
[Shilajit]
The generic name of shilajit used for the sebum production or accumulation inhibitor of the present invention is called mineral pitch, and the scientific name is Asphalt, Asphalt puniabiunum or Asphalt Punjabinum. This shilajit is a mixture of natural humus and plant organic matter collected in the highlands of the Himalayas at an altitude of 1000 to 5000 m, and contains more than 40 precious minerals such as fulvic acid and humic acid as its components. The shilajit used in the present invention preferably contains 5% by mass or more of fulvic acid, more preferably 10% by mass or more, and particularly preferably 20% by mass or more. In the present invention, a commercially available product can be used. The shape is not particularly limited, but is preferably in the form of powder.
本発明の皮脂の産生又は蓄積抑制剤、角化異常の予防又は改善剤、ニキビの予防又は改善剤は、例えば、医薬品（医薬部外品を含む）や、特定保健用食品、栄養機能食品、機能性表示食品等の所定機関より効能の表示が認められた機能性食品などのいわゆる健康食品等として用いることができる。 The agent for suppressing the production or accumulation of sebum, the agent for preventing or improving keratinization abnormality, and the agent for preventing or improving acne of the present invention include, for example, pharmaceuticals (including non-medicinal products), foods for specified health uses, foods with nutritional function, etc. It can be used as a so-called health food such as a functional food whose efficacy has been approved by a predetermined organization such as a food with a functional claim.
本発明の皮脂の産生又は蓄積抑制剤としては、シラジットを含有し、皮脂の産生又は蓄積の抑制に用いられる点において、製品として他の製品と区別することができるものであれば特に制限されるものではなく、例えば、本発明に係る製品の本体、包装、説明書、宣伝物（広告媒体）のいずれかに、皮脂産生又は蓄積の抑制機能、これに起因する各種症状の予防改善機能がある旨を表示したものが本発明の範囲に含まれる。なお、本発明の皮脂の産生又は蓄積抑制剤は、製品の包装等に、シラジットが有効成分として表示されているものに限られない。例えば、有効成分を特定していないものであってもよい。また、一般的な食品であっても、用途を示唆して製造販売されるものは本発明の範囲に含まれる。 The sebum production or accumulation inhibitor of the present invention is particularly limited as long as it contains siragit and can be distinguished from other products in that it is used for suppressing sebum production or accumulation. For example, any of the main body, packaging, instruction manual, and promotional material (advertising medium) of the product according to the present invention has a function of suppressing sebum production or accumulation, and a function of preventing and improving various symptoms caused by the function. The indication to that effect is included in the scope of the present invention. The sebum production or accumulation inhibitor of the present invention is not limited to the one in which shilajit is indicated as an active ingredient on the packaging of the product or the like. For example, the active ingredient may not be specified. Further, even general foods that are manufactured and sold by suggesting their uses are included in the scope of the present invention.
具体的に、いわゆる健康食品においては、「皮脂の産生を抑える」、「皮脂の分泌を抑える」、「ニキビを防ぐ」、「ニキビを改善する」、「肌のべたつきを抑える」、「肌のテカリを抑える」、「角栓を防ぐ」、「角栓を改善する」、「ポツポツが気になる方に」、「肌トラブル対策に」、「ポツポツ対策」、「ぶつぶつケア」、「すべすべケア」、「ツルンとケア」、「バランスケア」等を表示したものを例示することができる。本発明の皮脂の産生又は蓄積抑制剤を摂取する対象としては、上記各症状の予防改善を必要とする人であれば特に限定されないが、皮脂の分泌が活発な若者（例えば、１５〜３０歳）やホルモンバランスの乱れやストレスによりニキビができやすい大人（例えば、２５〜４０歳）を好ましく例示することができる。 Specifically, in so-called health foods, "suppress sebum production", "suppress sebum secretion", "prevent acne", "improve acne", "suppress skin stickiness", "skin stickiness" "Suppress shine", "Prevent keratin plugs", "Improve keratin plugs", "For those who are worried about spots", "For skin troubles", "Countermeasures for spots", "Bump care", "Smooth care" , "Turun and Care", "Balance Care", etc. can be illustrated. The target for ingesting the sebum production or accumulation inhibitor of the present invention is not particularly limited as long as it is a person who needs prevention and improvement of each of the above symptoms, but a young person with active sebum secretion (for example, 15 to 30 years old). ), Adults who are prone to acne due to imbalance of hormones and stress (for example, 25 to 40 years old) can be preferably exemplified.
本発明の角化異常の予防又は改善剤としては、シラジットを含有し、角化異常の予防又は改善に用いられる点において、製品として他の製品と区別することができるものであれば特に制限されるものではなく、例えば、本発明に係る製品の本体、包装、説明書、宣伝物（広告媒体）のいずれかに、角化異常の予防又は改善機能がある旨を表示したものが本発明の範囲に含まれる。なお、本発明の角化異常の予防又は改善剤は、製品の包装等に、シラジットが有効成分として表示されているものに限られない。例えば、有効成分を特定していないものであってもよい。また、一般的な食品であっても、用途を示唆して製造販売されるものは本発明の範囲に含まれる。 The preventive or ameliorating agent for keratinization abnormality of the present invention is particularly limited as long as it contains siragit and can be distinguished from other products as a product in that it is used for prevention or improvement of keratinization abnormality. However, for example, the product body, packaging, instruction manual, or promotional material (advertising medium) according to the present invention indicates that the product has a function of preventing or improving keratinization abnormality. Included in the range. The preventive or ameliorating agent for keratinization abnormality of the present invention is not limited to the one in which shilajit is displayed as an active ingredient on the packaging of the product or the like. For example, the active ingredient may not be specified. Further, even general foods that are manufactured and sold by suggesting their uses are included in the scope of the present invention.
具体的に、いわゆる健康食品においては、「皮脂の産生を抑える」、「皮脂の分泌を抑える」、「角化異常を防ぐ」、「角化異常を改善する」、「毛穴のつまりを防ぐ」、「毛穴のつまりを改善する」、「角栓を防ぐ」、「角栓を改善する」、「ポツポツが気になる方に」、「肌トラブル対策に」、「ポツポツ対策」、「ぶつぶつケア」、「すべすべケア」、「ツルンとケア」等を表示したものを例示することができる。本発明の角化異常の予防又は改善剤を摂取する対象としては、角化異常の予防改善を必要とする人であれば特に限定されないが、皮脂の分泌が活発な若者（例えば、１５〜３０歳）やホルモンバランスの乱れやストレスによりニキビができやすい大人（例えば、２５〜４０歳）を好ましく例示することができる。 Specifically, in so-called health foods, "suppress sebum production", "suppress sebum secretion", "prevent keratinization abnormalities", "improve keratinization abnormalities", "prevent pore clogging" , "Improves pore clogging", "Prevents keratin plugs", "Improves keratin plugs", "For those who are worried about spots", "For skin troubles", "Countermeasures for spots", "Bump care" , "Smooth care", "Tsurun and care", etc. can be illustrated. The target for ingesting the preventive or ameliorating agent for keratinization abnormality of the present invention is not particularly limited as long as it is a person who needs prevention and improvement of keratinization abnormality, but is a young person with active sebum secretion (for example, 15 to 30). An adult (for example, 25 to 40 years old) who is prone to acne due to imbalance of hormones or stress can be preferably exemplified.
本発明のニキビの予防又は改善剤としては、シラジットを含有し、ニキビの予防又は改善に用いられる点において、製品として他の製品と区別することができるものであれば特に制限されるものではなく、例えば、本発明に係る製品の本体、包装、説明書、宣伝物（広告媒体）のいずれかに、ニキビの予防又は改善機能がある旨を表示したものが本発明の範囲に含まれる。なお、本発明のニキビの予防又は改善剤は、製品の包装等に、シラジットが有効成分として表示されているものに限られない。例えば、有効成分を特定していないものであってもよい。また、一般的な食品であっても、用途を示唆して製造販売されるものは本発明の範囲に含まれる。 The acne preventive or ameliorating agent of the present invention is not particularly limited as long as it contains siragit and can be distinguished from other products as a product in that it is used for the prevention or amelioration of acne. For example, the scope of the present invention includes any one of the main body, packaging, instruction manual, and promotional material (advertising medium) of the product according to the present invention indicating that it has a function of preventing or improving acne. The acne preventive or ameliorating agent of the present invention is not limited to the one in which shilajit is indicated as an active ingredient on the packaging of the product or the like. For example, the active ingredient may not be specified. Further, even general foods that are manufactured and sold by suggesting their uses are included in the scope of the present invention.
具体的に、いわゆる健康食品においては、「皮脂の産生を抑える」、「皮脂の分泌を抑える」、「ニキビを防ぐ」、「ニキビを改善する」、「毛穴のつまりを防ぐ」、「毛穴のつまりを改善する」、「角栓を防ぐ」、「角栓を改善する」、「ポツポツが気になる方に」、「肌トラブル対策に」、「ポツポツ対策」、「ぶつぶつケア」、「すべすべケア」、「ツルンとケア」等を表示したものを例示することができる。本発明のニキビの予防又は改善剤を摂取する対象としては、ニキビの予防改善を必要とする人であれば特に限定されないが、皮脂の分泌が活発な若者（例えば、１５〜３０歳）やホルモンバランスの乱れやストレスによりニキビができやすい大人（例えば、２５〜４０歳）を好ましく例示することができる。 Specifically, in so-called health foods, "suppress sebum production", "suppress sebum secretion", "prevent acne", "improve acne", "prevent clogging of pores", "prevent pore clogging", "pore In other words, "improve", "prevent keratin plugs", "improve keratin plugs", "for those who are worried about spots", "for skin troubles", "countermeasures for spots", "bump care", "smoothness" Examples of those displaying "care", "trun and care", etc. can be exemplified. The target for taking the acne preventive or ameliorating agent of the present invention is not particularly limited as long as it is a person who needs the preventive and ameliorating acne, but young people (for example, 15 to 30 years old) with active sebum secretion and hormones. Adults (eg, 25-40 years old) who are prone to acne due to imbalance or stress can be preferably exemplified.
本発明の皮脂の産生又は蓄積抑制剤、角化異常の予防又は改善剤、ニキビの予防又は改善剤の形態としては、例えば、錠状、カプセル状、粉末状、顆粒状、液状、粒状、棒状、板状、ブロック状、固形状、丸状、ペースト状、クリーム状、カプレット状、ゲル状、チュアブル錠状、スティック状等を挙げることができる。これらの中でも、錠状、カプセル状、粉末状、顆粒状、丸状、チュアブル錠状の形態が好ましく、錠状、カプセル状、丸状、チュアブル錠状がより好ましい。 The forms of the sebum production or accumulation inhibitor, the keratinization abnormality prevention or ameliorating agent, and the acne prevention or ameliorating agent of the present invention include, for example, tablets, capsules, powders, granules, liquids, granules, and rods. , Plate-shaped, block-shaped, solid-shaped, round-shaped, paste-shaped, cream-shaped, capsule-shaped, gel-shaped, chewable tablet-shaped, stick-shaped and the like. Among these, the tablet-shaped, capsule-shaped, powder-shaped, granular-shaped, round-shaped, and chewable tablet-shaped forms are preferable, and the tablet-shaped, capsule-shaped, round-shaped, and chewable tablet-shaped are more preferable.
本発明の皮脂の産生又は蓄積抑制剤、角化異常の予防又は改善剤、ニキビの予防又は改善剤を錠状、丸状、チュアブル錠状とする場合、賦形剤、滑沢剤、流動化剤のいずれか１種以上を添加することにより、成型性を高めるとともに得られた錠剤、丸剤又はチュアブル錠剤の保存安定性を向上するため、好ましい。特に、賦形剤、滑沢剤を使用することで保存安定性をより高めることができる。 When the sebum production or accumulation inhibitor, the preventive or ameliorating agent for keratinization abnormality, and the preventive or ameliorating agent for acne of the present invention are in the form of tablets, pills, or chewable tablets, excipients, pills, fluidization It is preferable to add any one or more of the agents because the moldability is improved and the storage stability of the obtained tablets, pills or chewable tablets is improved. In particular, the storage stability can be further enhanced by using excipients and lubricants.
賦形剤とは、組成物の取扱いあるいは成形の向上や服用を便利にするために加えるものである。本発明に使用できる賦形剤としては特に制限はなく、例えば、デンプン、アルファー化デンプン、部分アルファー化デンプン、デンプン分解物等のデンプン又はその誘導体、結晶セルロース、糖アルコール、乳糖、ビール酵母、低置換度ヒドロキシプロピルセルロース、ヒドロキシプロピルセルロース、精製白糖、軽質無水ケイ酸、ケイ酸カルシウム、酸化チタン、沈降炭酸カルシウム等などが挙げられる。これらは、１種単独で使用してもよいし、２種以上を併用してもよい。 Excipients are added to improve the handling or molding of the composition and to make it more convenient to take. The excipient that can be used in the present invention is not particularly limited, and is, for example, starch, pregelatinized starch, partially pregelatinized starch, starch such as starch decomposition product or a derivative thereof, crystalline cellulose, sugar alcohol, lactose, beer yeast, low. Substitution degree Hydroxypropyl cellulose, hydroxypropyl cellulose, purified sucrose, light anhydrous silicic acid, calcium silicate, titanium oxide, precipitated calcium carbonate and the like can be mentioned. These may be used alone or in combination of two or more.
滑沢剤とは、錠剤用の粉末を圧縮する際に打錠機杵臼と錠剤間の摩擦を緩和し、スティッキングなどの打錠障害を防ぐために使用するものである。本発明に使用できる滑沢剤としては、上記目的を達成することが可能な成分であれば特に制限はなく、例えば、ステアリン酸、ステアリン酸カルシウム、ステアリン酸マグネシウム等のステアリン酸又はその塩、フマル酸ステアリルナトリウム、ショ糖脂肪酸エステル、タルク、ポリエチレングリコール、植物油脂、硬化油などが挙げられる。これらは、１種単独で使用してもよく、２種以上を併用してもよい。 The lubricant is used to alleviate the friction between the tableting machine pestle and the tablet when compressing the powder for tablets, and to prevent tableting obstacles such as sticking. The lubricant that can be used in the present invention is not particularly limited as long as it is a component capable of achieving the above object. For example, stearic acid such as stearic acid, calcium stearate, magnesium stearate or a salt thereof, fumaric acid. Examples thereof include stearyl sodium, sucrose fatty acid ester, talc, polyethylene glycol, vegetable oil and fat, and hydrogenated oil. These may be used alone or in combination of two or more.
流動化剤とは、混合末や顆粒の流動性を改善するために使用するものである。本発明に使用できる流動化剤としては特に制限はなく、例えば二酸化ケイ素、ケイ酸アルミニウム、ケイ酸アルミン酸マグネシウム、リン酸カルシウム、炭酸マグネシウム、酸化マグネシウムなどが挙げられる。これらは、１種単独で使用してもよいし、２種以上を併用してもよい。本発明において、賦形剤、滑沢剤、流動化剤はいずれも市販品を使用することができる。 The fluidizing agent is used to improve the fluidity of mixed powders and granules. The fluidizing agent that can be used in the present invention is not particularly limited, and examples thereof include silicon dioxide, aluminum silicate, magnesium silicate aluminate, calcium phosphate, magnesium carbonate, and magnesium oxide. These may be used alone or in combination of two or more. In the present invention, commercially available products can be used as the excipient, the lubricant, and the fluidizing agent.
本発明の皮脂の産生又は蓄積抑制剤、角化異常の予防又は改善剤、ニキビの予防又は改善剤におけるシラジットの含有量としては、その効果の奏する範囲で適宜含有させればよい。 The content of shilajit in the sebum production or accumulation inhibitor, the keratinization abnormality prevention or ameliorating agent, and the acne prevention or ameliorating agent of the present invention may be appropriately contained within the range in which the effect is exhibited.
具体的には、本発明の皮脂の産生又は蓄積抑制剤、角化異常の予防又は改善剤、ニキビの予防又は改善剤が錠状、丸状、カプセル状、チュアブル錠状の場合には、その作用を一層高める点から、乾燥質量換算で全体の０．０１〜１００質量％含まれていることが好ましく、０．１〜８０質量％含まれていることがより好ましく、１〜６０質量％含まれていることが特に好ましい。粉末状、顆粒状の場合、その作用を一層高める点から、乾燥質量換算で全体の０．１〜１００質量％含まれていることが好ましく、１〜７５質量％含まれていることがより好ましく、１０〜５０質量％含まれていることが特に好ましい。液状の場合、その作用を一層高める点から、乾燥質量換算で全体の０．０１〜１００質量％含まれていることが好ましく、０．１〜７０質量％含まれていることがより好ましく、１〜４０質量％含まれていることが特に好ましい。 Specifically, when the sebum production or accumulation inhibitor, the keratinization abnormality prevention or ameliorating agent, and the acne prevention or ameliorating agent of the present invention are in the form of tablets, rounds, capsules, or chewable tablets, the same. From the viewpoint of further enhancing the action, it is preferably contained in an amount of 0.01 to 100% by mass, more preferably 0.1 to 80% by mass, and 1 to 60% by mass in terms of dry mass. It is particularly preferable that In the case of powder or granules, it is preferably contained in an amount of 0.1 to 100% by mass, more preferably 1 to 75% by mass in terms of dry mass, from the viewpoint of further enhancing the action. , 10 to 50% by mass is particularly preferable. In the case of a liquid, it is preferably contained in an amount of 0.01 to 100% by mass, more preferably 0.1 to 70% by mass, in terms of dry mass, from the viewpoint of further enhancing its action. It is particularly preferable that the content is ~ 40% by mass.
本発明の皮脂の産生又は蓄積抑制剤、角化異常の予防又は改善剤、ニキビの予防又は改善剤の摂取量としては特に制限はないが、その作用を一層高める点から、成人の１日当たり、シラジットの摂取量が、０．０１ｍｇ以上となるように摂取することが好ましく、０．１ｍｇ以上となるように摂取することがより好ましく、１ｍｇ以上となるように摂取することがさらに好ましい。その上限は、例えば、１０００ｍｇであり、好ましくは７５０ｍｇであり、より好ましくは５００ｍｇである。 The intake of the sebum production or accumulation inhibitor, the keratinization abnormality prevention or ameliorating agent, and the acne prevention or ameliorating agent of the present invention is not particularly limited, but from the viewpoint of further enhancing its action, per day for adults. The intake of siragit is preferably 0.01 mg or more, more preferably 0.1 mg or more, and even more preferably 1 mg or more. The upper limit is, for example, 1000 mg, preferably 750 mg, and more preferably 500 mg.
本発明の皮脂の産生又は蓄積抑制剤、角化異常の予防又は改善剤、ニキビの予防又は改善剤は、１日の摂取量が前記摂取量となるように適宜設計すればよく、１回で摂取してもよいし、複数回に分けて摂取してもよい。例えば、錠剤、カプセル剤、丸剤又はチュアブル錠剤の場合は１日あたり１〜４回の摂取回数とし、合計量として前記摂取量が摂取できればよく、飲料の場合、１日の摂取量に前記摂取量が配合されていればよい。本発明の皮脂の産生又は蓄積抑制剤、角化異常の予防又は改善剤、ニキビの予防又は改善剤は、１日の摂取量が前記摂取量となるように、１つの容器に、又は例えば２〜３の複数の容器に分けて、１日分として収容することができる。 The sebum production or accumulation inhibitor, the keratinization abnormality prevention or ameliorating agent, and the acne prevention or ameliorating agent of the present invention may be appropriately designed so that the daily intake is the above-mentioned intake amount. It may be taken or may be taken in multiple doses. For example, in the case of tablets, capsules, pills or chewable tablets, the number of intakes should be 1 to 4 times a day, and the total amount should be the intake, and in the case of beverages, the intake should be the daily intake. It suffices if the amount is mixed. The sebum production or accumulation inhibitor, the keratinization abnormality preventive or ameliorating agent, and the acne preventive or ameliorating agent of the present invention are placed in one container or, for example, 2 so that the daily intake becomes the above-mentioned intake amount. It can be divided into a plurality of containers of ~ 3 and stored as one day's worth.
本発明の皮脂の産生又は蓄積抑制剤、角化異常の予防又は改善剤、ニキビの予防又は改善剤は、必要に応じて、シラジット以外の他の成分を添加して、公知の方法によって製造することができる。他の成分としては、例えば、水溶性ビタミン（ビタミンＢ１、Ｂ２、Ｂ３、Ｂ５、Ｂ６、Ｂ１２、Ｂ１３、Ｂ１５、Ｂ１７、ビオチン、コリン、葉酸、イノシトール、ＰＡＢＡ、ビタミンＣ、ビタミンＰ）、油溶性ビタミン（ビタミンＡ、Ｄ、Ｅ、Ｋ）等のビタミン類；マグネシウム、リン、亜鉛、鉄等のミネラル類；タウリン、ニンニク等に含まれる含硫化合物；ヘスペリジン、ケルセチン等のフラバノイド或いはフラボノイド類；コラーゲン等のタンパク質；ペプチド；アミノ酸；動物性油脂；植物性油脂；動物・植物の粉砕物又は抽出物等を挙げることができる。 The sebum production or accumulation inhibitor, the keratinization abnormality prevention or ameliorating agent, and the acne prevention or ameliorating agent of the present invention are produced by a known method by adding other components other than shilajit, if necessary. be able to. Other components include, for example, water-soluble vitamins (vitamins B1, B2, B3, B5, B6, B12, B13, B15, B17, biotin, choline, folic acid, inositol, PABA, vitamin C, vitamin P), oil-soluble. Vitamins such as vitamins (vitamins A, D, E, K); minerals such as magnesium, phosphorus, zinc, iron; sulfur-containing compounds contained in taurine, garlic, etc .; flavanoids or flavonoids such as hesperidin, quercetin; collagen Proteins such as; peptides; amino acids; animal fats and oils; vegetable fats and oils; crushed products or extracts of animals and plants.
１．サンプル調製
（実施例１）
シラジットとして、シラジットの原石の水抽出物（乾燥粉末）を用いた。具体的には、シラジットの原石を水で抽出した抽出液をろ過した後、乾燥させた粉末状の抽出物を用いた。シラジット濃度が1mg/mLとなるように0.5%DMSO-増殖培地で調製し、チューブミキサーで30分ボルテックス後、遠心（15,000g×5分、室温）して上清を回収した。
1. 1. Sample preparation (Example 1)
As shilajit, a water extract (dry powder) of rough shilajit was used. Specifically, a powdery extract obtained by filtering an extract obtained by extracting rough shilajit with water and then drying it was used. The mixture was prepared in 0.5% DMSO-proliferation medium so that the shilajit concentration was 1 mg / mL, vortexed with a tube mixer for 30 minutes, and then centrifuged (15,000 g × 5 minutes, room temperature) to collect the supernatant.
なお、増殖培地としては、P/S（Penicillin-Streptomycin）を1%添加したDMEMとHAM's F-12（富士フイルム和光純薬（株））を等量混合し、以下の添加剤（終濃度）を加えたものを用いた（以下同様）。
・8% FBS
・2% Human Serum
・3.4mM L-Glutamine
・10ng/mL EGF
As the growth medium, DMEM supplemented with 1% of P / S (Penicillin-Streptomycin) and HAM's F-12 (Fujifilm Wako Pure Chemical Industries, Ltd.) were mixed in equal amounts, and the following additives (final concentration) were mixed. Was used (the same applies hereinafter).
・ 8% FBS
・ 2% Human Serum
・ 3.4mM L-Glutamine
・ 10ng / mL EGF
（参考例１）
ポジティブコントロールとして、ニキビ薬の有効成分として知られているatRT（all-trans-Retinoic Acid）を用いた。atRT 濃度が3mg/mLとなるようにDMSOで調製し、チューブミキサーで30分ボルテックス後、遠心（15,000g×5分、室温）して上清を回収した。DMSOを用いて所定濃度に希釈し、増殖培地と混合した（DMSO濃度は0.5%）。
(Reference example 1)
As a positive control, atRT (all-trans-Retinoic Acid), which is known as an active ingredient of acne drugs, was used. It was prepared by DMSO so that the atRT concentration was 3 mg / mL, vortexed with a tube mixer for 30 minutes, and then centrifuged (15,000 g × 5 minutes, room temperature) to collect the supernatant. Diluted to a given concentration using DMSO and mixed with growth medium (DMSO concentration 0.5%).
２．ハムスター由来皮脂腺細胞における脂肪産生又は蓄積抑制作用の評価
皮脂腺細胞は皮脂を産生して顆粒に蓄積したのち、皮脂を分泌することが知られており、ハムスター由来皮脂腺細胞はニキビや脂漏症などを予防又は改善する種々の物質の評価に使用されている。以下に、評価手順を記載する。
（１）37℃、5%CO2インキュベーター内で、75cm2フラスコを用いて、ハムスター由来皮脂腺細胞（Ha-SE）を増殖培地により培養した。
（２）トリプシン処理により浮遊させた細胞を増殖培地に懸濁し、75cm2フラスコから24well plateの各wellに4.5×104cells/wellの細胞密度で播種した。
（３）37℃、5%CO2インキュベーター内で約24時間前培養した。
（４）各wellより溶液を除去後、無血清DMEMで洗浄し、所定濃度に調製した被験物質含有分化誘導培地（サンプル）を350μLずつ添加し、CO2インキュベーター内で、2〜3回／週 培地交換を行いながら、13日間培養した。なお、コントロールは被験物質を含有しない分化誘導培地を350μL添加した。
2. Evaluation of sebum production or accumulation inhibitory action in hamster-derived sebaceous gland cells It is known that sebaceous gland cells produce sebum, accumulate in granules, and then secrete sebum. It is used to evaluate various substances that prevent or improve. The evaluation procedure is described below.
(1) Hamster-derived sebaceous gland cells (Ha-SE) were cultured in a growth medium in a 5% CO 2 incubator at 37 ° C. using a 75 cm 2 flask.
(2) Cells suspended by trypsin treatment were suspended in growth medium and seeded from a 75 cm 2 flask to each well of a 24-well plate at a cell density of 4.5 × 10 4 cells / well.
(3) Pre-cultured in a 5% CO 2 incubator at 37 ° C for about 24 hours.
(4) After removing the solution from each well, wash with serum-free DMEM, add 350 μL of the test substance-containing differentiation-inducing medium (sample) prepared to a predetermined concentration, and in a CO 2 incubator, 2 to 3 times / week. The cells were cultured for 13 days while exchanging the medium. For the control, 350 μL of a differentiation-inducing medium containing no test substance was added.
なお、分化誘導培地としては、P/Sを1%添加したDMEMとHAM's F-12（富士フイルム和光純薬（株））を等量混合し、以下の添加剤（終濃度）を加えたものを用いた（以下同様）。
・8% FBS
・2% Human Serum
・3.4mM L-Glutamine
・10nM Insulin
As the differentiation-inducing medium, DMEM supplemented with 1% P / S and HAM's F-12 (Fuji Film Wako Pure Chemical Industries, Ltd.) were mixed in equal amounts, and the following additives (final concentration) were added. Was used (the same applies hereinafter).
・ 8% FBS
・ 2% Human Serum
・ 3.4mM L-Glutamine
・ 10nM Insulin
（５）各wellより培地を除去後、無血清DMEMで洗浄し、無血清DMEMで30倍に希釈したCell Counting Kit-8溶液（同仁化学研究所）を100μLずつ添加した。
（６）37℃、5％CO2インキュベーター内に静置し30分発色させた後、450nmにおける吸光度を測定した。
（７）得られたデータを元に「% of control」を算出し、細胞数の相対値を算出した。
% of control
= (Data sample−Data blank) ／（Data control−Data blank）×100
(5) After removing the medium from each well, the cells were washed with serum-free DMEM, and 100 μL of Cell Counting Kit-8 solution (Dojin Chemical Laboratory) diluted 30-fold with serum-free DMEM was added.
(6) After allowing to stand in a 5% CO 2 incubator at 37 ° C. for 30 minutes to develop color, the absorbance at 450 nm was measured.
(7) Based on the obtained data, "% of control" was calculated, and the relative value of the number of cells was calculated.
% of control
= (Data sample-Data blank) / (Data control-Data blank) x 100
（８）上清を除去し、PBSで1回洗浄した。
（９）上清を除去し、10%-Formaldehyde Neutral Bufferを200μL添加し、室温で10分静置した。
（１０）上清を除去し、PBSで2回洗浄した。
（１１）上清を除去し、60% 2-Propanolを500μL添加し、室温で1分静置した。
（１２）上清を除去し、Oil Red O溶液を300μL添加し、室温で30分静置した。
（１３）上清を除去し、60% 2-Propanol 500μLで2回洗浄した。
(8) The supernatant was removed and washed once with PBS.
(9) The supernatant was removed, 200 μL of 10% -Formaldehyde Neutral Buffer was added, and the mixture was allowed to stand at room temperature for 10 minutes.
(10) The supernatant was removed, and the mixture was washed twice with PBS.
(11) The supernatant was removed, 500 μL of 60% 2-Propanol was added, and the mixture was allowed to stand at room temperature for 1 minute.
(12) The supernatant was removed, 300 μL of Oil Red O solution was added, and the mixture was allowed to stand at room temperature for 30 minutes.
(13) The supernatant was removed, and the mixture was washed twice with 500 μL of 60% 2-Propanol.
（１４）上清を除去し、PBS 500μLを添加し細胞染色像の撮影を行った。
（１５）上清を除去し、100% 2-Propanol を300μL添加してプレートシェーカーを用いて室温で5分間振盪した。
（１６）上清200μLを96wellプレートへ回収し、530nmにおける吸光度を測定した。
（１７）得られたデータを元に「% of control」を算出し、皮脂が産生されて蓄積された量の相対値を算出した。
% of control
= (Data sample−Data blank) ／（Data control−Data blank）×100
（１８）さらに、（７）の結果より、同一細胞数あたりの脂肪が産生されて蓄積された量を算出した。
(14) The supernatant was removed, 500 μL of PBS was added, and a cell-stained image was taken.
(15) The supernatant was removed, 300 μL of 100% 2-Propanol was added, and the mixture was shaken at room temperature for 5 minutes using a plate shaker.
(16) 200 μL of the supernatant was collected on a 96-well plate, and the absorbance at 530 nm was measured.
(17) Based on the obtained data, "% of control" was calculated, and the relative value of the amount of sebum produced and accumulated was calculated.
% of control
= (Data sample-Data blank) / (Data control-Data blank) x 100
(18) Furthermore, from the result of (7), the amount of fat produced and accumulated per the same number of cells was calculated.
その結果を表１に示す。 The results are shown in Table 1.
実施例１のシラジットにハムスター皮脂線細胞における脂肪産生又は蓄積抑制作用が認められた。脂肪蓄積量は、controlに対して71%に抑制された。この抑制効果は、現在ニキビ薬の有効成分として認められている参考例１のatRTと遜色ない効果である。本発明の組成物は、皮脂の産生又は蓄積抑制剤、角化異常の予防又は改善剤、ニキビの予防又は改善剤として有効である。 Shilajit of Example 1 was found to have an inhibitory effect on fat production or accumulation in hamster sebum line cells. The amount of fat accumulated was suppressed to 71% with respect to control. This inhibitory effect is comparable to atRT of Reference Example 1, which is currently recognized as an active ingredient of acne drugs. The composition of the present invention is effective as an agent for suppressing the production or accumulation of sebum, an agent for preventing or improving abnormal keratinization, and an agent for preventing or improving acne.
［配合実施例１］
下記成分からなる錠剤（１粒あたり２５０ｍｇ）を製造した。得られた錠剤を１日あたり２粒摂取することで、優れた皮脂産生又は蓄積抑制効果、角化異常予防又は改善効果、又はニキビ予防又は改善効果が得られる。
[Formulation Example 1]
A tablet (250 mg per tablet) consisting of the following components was produced. By ingesting two of the obtained tablets per day, an excellent sebum production or accumulation inhibitory effect, a keratinization abnormality prevention or improvement effect, or an acne prevention or improvement effect can be obtained.
［配合実施例２］
下記成分からなるカプセル（１カプセルあたりの内容物３００ｍｇ）を製造した。得られた錠剤を１日あたり６粒摂取することで、優れた皮脂産生又は蓄積抑制効果、角化異常予防又は改善効果、又はニキビ予防又は改善効果が得られる。
[Formulation Example 2]
A capsule consisting of the following components (300 mg of content per capsule) was produced. By ingesting 6 tablets per day, an excellent sebum production or accumulation suppressing effect, keratinization abnormality prevention or improvement effect, or acne prevention or improvement effect can be obtained.
［配合実施例３］
下記成分からなる顆粒剤（１包あたり２ｇ）を製造した。得られた顆粒剤を１日あたり１包摂取することで、優れた皮脂産生又は蓄積抑制効果、角化異常予防又は改善効果、又はニキビ予防又は改善効果が得られる。
[Formulation Example 3]
Granules (2 g per packet) consisting of the following components were produced. By ingesting one packet of the obtained granules per day, an excellent sebum production or accumulation suppressing effect, keratinization abnormality prevention or improvement effect, or acne prevention or improvement effect can be obtained.
［配合実施例４］
下記成分からなる液剤（１本あたり５０ｍｌ）を製造した。得られた液剤を１日１回摂取することで、優れた皮脂産生又は蓄積抑制効果、角化異常予防又は改善効果、又はニキビ予防又は改善効果が得られる。
[Formulation Example 4]
A liquid preparation (50 ml per bottle) consisting of the following components was produced. By ingesting the obtained liquid once a day, an excellent sebum production or accumulation suppressing effect, keratinization abnormality prevention or improvement effect, or acne prevention or improvement effect can be obtained.
本発明の皮脂の産生又は蓄積抑制剤、角化異常の予防又は改善剤、ニキビの予防又は改善剤は、健康食品等として用いることができることから、産業上の有用性は高い。 Since the sebum production or accumulation inhibitor, the keratinization abnormality prevention or ameliorating agent, and the acne prevention or ameliorating agent of the present invention can be used as health foods and the like, they are highly industrially useful.
Claims (3)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019164297A JP2021042151A (en) | 2019-09-10 | 2019-09-10 | Agent for inhibiting sebum production or accumulation, agent for preventing or improving dyskeratosis, and agent for preventing or improving acne |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019164297A JP2021042151A (en) | 2019-09-10 | 2019-09-10 | Agent for inhibiting sebum production or accumulation, agent for preventing or improving dyskeratosis, and agent for preventing or improving acne |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2021042151A true JP2021042151A (en) | 2021-03-18 |
Family
ID=74863641
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019164297A Pending JP2021042151A (en) | 2019-09-10 | 2019-09-10 | Agent for inhibiting sebum production or accumulation, agent for preventing or improving dyskeratosis, and agent for preventing or improving acne |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2021042151A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017530980A (en) * | 2014-10-02 | 2017-10-19 | ナトレオン，インコーポレイテッド | Use of Shilajit to promote muscle build-up and repair and treat disorders related to collagen and related proteins |
| JP2019019108A (en) * | 2017-07-20 | 2019-02-07 | 学校法人 中村産業学園 | 5α-REDUCTASE INHIBITOR, AND COMPOSITION FOR PREVENTIVE TREATMENT OF ALOPECIA OR HAIR GROWTH PROMOTION, AND METHOD FOR INHIBITING 5α-REDUCTASE IN SCALP AND HAIR GROWTH PROMOTION METHOD |
| WO2019146790A1 (en) * | 2018-01-29 | 2019-08-01 | 株式会社スタイルアンドバリュージャパン | Food composition for ameliorating or preventing lifestyle-related diseases |
-
2019
- 2019-09-10 JP JP2019164297A patent/JP2021042151A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017530980A (en) * | 2014-10-02 | 2017-10-19 | ナトレオン，インコーポレイテッド | Use of Shilajit to promote muscle build-up and repair and treat disorders related to collagen and related proteins |
| JP2019019108A (en) * | 2017-07-20 | 2019-02-07 | 学校法人 中村産業学園 | 5α-REDUCTASE INHIBITOR, AND COMPOSITION FOR PREVENTIVE TREATMENT OF ALOPECIA OR HAIR GROWTH PROMOTION, AND METHOD FOR INHIBITING 5α-REDUCTASE IN SCALP AND HAIR GROWTH PROMOTION METHOD |
| WO2019146790A1 (en) * | 2018-01-29 | 2019-08-01 | 株式会社スタイルアンドバリュージャパン | Food composition for ameliorating or preventing lifestyle-related diseases |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7373869B2 (en) | Oral composition | |
| RU2493865C2 (en) | Using ginkgo biloba leaf extract | |
| JP2008148610A (en) | Collagen-containing food product | |
| JPWO2019230233A1 (en) | Devil's Claw Extract, various compositions containing it, and method for producing Devil's Claw Extract | |
| JP6889879B2 (en) | Chewable tablet | |
| JP2008214338A (en) | Agent for ameliorating lowering of high-order brain function and agent for ameliorating lowering of short-term memory | |
| WO2019163176A1 (en) | Osteoclast differentiation inhibitor containing urolithin | |
| CN108289875A (en) | Threose acid salt compound and its application method | |
| JP2021042151A (en) | Agent for inhibiting sebum production or accumulation, agent for preventing or improving dyskeratosis, and agent for preventing or improving acne | |
| JP6923065B1 (en) | Oral solid composition | |
| CN104147146A (en) | Pharmaceutical composition capable of promoting excretion of lead, and preparation method and application thereof | |
| JP6742575B2 (en) | Joint function improving composition | |
| WO2005070435A1 (en) | Agent for improving dynamic eyesight | |
| JP5836520B1 (en) | Blood neutral fat elevation inhibitor | |
| JP6841444B2 (en) | Immunostimulant | |
| JP6757995B2 (en) | Oral composition | |
| JP6266546B2 (en) | Cartilage protection and joint protection | |
| JP2011225504A5 (en) | ||
| JP2021054770A (en) | Beauty composition | |
| JP7497006B2 (en) | Phosphodiesterase 5A1 activity inhibitor, muscle relaxant or contraction inhibitor, urinary disorder prevention or improvement agent | |
| JP6948774B2 (en) | Preadipocyte differentiation inhibitor containing urolithins | |
| JP2016531931A (en) | Cocoa polyphenols and their use in the treatment or prevention of eosinophilic esophagitis | |
| JP2015096498A (en) | Ages decomposer | |
| JP7257715B2 (en) | oral composition | |
| JP2014224074A (en) | Elastase activity inhibitor comprising extracts of salicaceous salix plant |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220816 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230612 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230614 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20231205 |